What is Mandrake Bioworks?
Mandrake Bioworks operates as an AI-native biotechnology enterprise, specializing in the development of next-generation gene-editing proteins. The company leverages a full-stack platform that synthesizes computational biology, generative artificial intelligence, and rigorous experimental validation. This integrated approach allows for the rapid engineering of novel molecular tools designed to enhance the precision and efficiency of gene-editing processes. By bridging the gap between digital modeling and physical biological outcomes, the firm addresses significant bottlenecks in therapeutic development and agricultural productivity, positioning itself at the intersection of high-tech innovation and life sciences.
How much funding has Mandrake Bioworks raised?
Mandrake Bioworks has raised a total of $1.7M across 1 funding round:
Angel/Pre-Seed
$1.7M
Angel/Pre-Seed (2026): $1.7M with participation from DeVC, Spectrum Impact, and Antler
Key Investors in Mandrake Bioworks
DeVC
A collective of founders, operators, and investors that provides early-stage capital and operational support to ambitious entrepreneurs building transformative companies.
Spectrum Impact
A family office focused on allocating capital toward large-scale societal issues, optimizing for financial, environmental, and social returns.
Antler
A global early-stage venture capital firm that partners with exceptional founders across six continents to launch and scale startups addressing meaningful global challenges.
What's next for Mandrake Bioworks?
With this major enterprise-level funding, Mandrake Bioworks is poised to scale its operational capacity and expand its experimental validation infrastructure. The strategic roadmap focuses on deepening the integration of its generative AI models to further refine protein design capabilities, thereby reducing the time-to-market for novel gene-editing solutions. As the company moves into its next phase of growth, the focus will likely shift toward establishing key partnerships within the pharmaceutical and agricultural industries to validate its molecular tools at scale. This capital deployment will be instrumental in maintaining the firm's competitive edge in the rapidly evolving field of synthetic biology, ensuring that its technological advancements translate into tangible, high-impact outcomes for global health and food security.
See full Mandrake Bioworks company page
